ERBB2 and cancer: Table 1 summarizes the baseline characteristics of the cohorts with ILC and IDC. Compared with patients with IDC, those with ILC were significantly older, had lower grades, had more advanced cancer stages, and were more likely to have hormone receptor–positive and ERBB2-negative breast cancer.